doi:10.12114/j.issn.1007-9572.2021.02.054

Abstract

Abstract: Background

In comparison to the general population, obese patients with polycystic ovary syndrome (PCOS) have a higher prevalence of nonalcoholic fatty liver disease (NAFLD) . Transaminase is a common indicator for the occurrence and severity of NAFLD. However, there are few studies have investigated associated factors of elevated transaminase in obese PCOS patients.

Objective

To investigate the associated factors of elevated transaminase in female obese PCOS patients.

Methods

One hundred and sixteen female patients were selected from the Endocrine Clinic, Shengjing Hospital of China Medical University from January 2020 to June 2021, comprising 77 obese PCOS patients, and 39 age- and BMI-matched simple obese patients. The demographic data, body composition analysis and biochemical test results of the two groups were comparatively analyzed to explore intergroup differences. The associated factors and independent risk factors for elevated transaminase in obese PCOS patients were explored.

Results

Obese PCOS patients had much higher average levels of ALT, AST, triacylglycerol (TG) , total cholesterol (TC) , low-density lipoprotein (LDL) , apolipoprotein B (ApoB) , luteinizing hormone (LH) , testosterone, fasting insulin (FIns) , homeostatic model assessment for insulin resistance (HOMA-IR) , free androgen index (FAI) and LH/follicle stimulating hormone (FSH) ratio, and much lower average levels of high-density lipoprotein (HDL) and sex hormone binding globulin (SHBG) than simple obese patients (P<0.05) . Two groups had no significant differences in average age, BMI, waist circumference, waist-to-hip ratio, body fat percentage, visceral fat area, fasting blood glucose, apolipoprotein A1, FSH, prolactin, progesterone and estradiol (P>0.05) . Spearman correlation analysis showed that transaminase was positively correlated with TG, TC, LDL, ApoB, testosterone, FIns, HOMA-IR and FAI (P<0.05) . Transaminase was negatively correlated with HDL (P<0.05) . Transaminase had no linear correlation with LH, SHBG and LH/FSH ratio (P>0.05) . Multivariate Logistic regression showed that increased testosterone was an independent risk factor for elevated transaminase in obese PCOS patients〔OR=6.339, 95%CI (1.834, 21.906) , P=0.004〕.

Conclusion

Elevated transaminase may be associated with lipid metabolism disorder, insulin resistance and hyperandrogenism, and increased testosterone was an independent risk factor for elevated transaminase in obese PCOS patients.

Key words: Polycystic ovary syndrome, Obesity, Transaminase, Testosterone, Insulin resistance, Lipid metabolism

摘要： 背景

肥胖多囊卵巢综合征（PCOS）患者合并非酒精性脂肪性肝病（NAFLD）的患病率明显高于普通人群，转氨酶是反映NAFLD发生和严重程度的常见指标，目前关于肥胖PCOS患者合并转氨酶升高的影响因素的研究较少。

目的

探讨肥胖PCOS患者转氨酶升高的相关影响因素。

方法

纳入2020年1月至2021年6月中国医科大学附属盛京医院内分泌门诊诊治的女性肥胖PCOS患者77例为研究对象（肥胖PCOS组），并纳入同期于该门诊就诊的年龄和体质指数相匹配的女性单纯肥胖患者39例为对照（单纯肥胖组）。回顾性分析两组患者的一般资料、人体成分分析及生化检验结果，比较两组间的差异；分析肥胖PCOS患者合并转氨酶升高的相关因素及独立危险因素。

结果

肥胖PCOS组的丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）、三酰甘油（TG）、总胆固醇（TC）、低密度脂蛋白（LDL）、载脂蛋白B（ApoB）、黄体生成素（LH）、睾酮（T）、空腹胰岛素（FIns）、稳态模型胰岛素抵抗指数（HOMA-IR）、游离雄激素指数（FAI）、LH/卵泡刺激素（FSH）高于单纯肥胖组（P<0.05），肥胖PCOS组的高密度脂蛋白（HDL）、性激素结合球蛋白（SHBG）低于单纯肥胖组（P<0.05），两组年龄、体质指数、腰围、腰臀比、体脂百分比、内脏脂肪面积、空腹血糖、载脂蛋白A1、FSH、泌乳素、孕酮、雌二醇间差异无统计学意义（P>0.05）。Spearman秩相关分析显示转氨酶与TG、TC、LDL、ApoB、T、FIns、HOMA-IR、FAI呈正相关（P<0.05），与HDL呈负相关（P<0.05），与LH、SHBG、LH/FSH无直线相关性（P>0.05）。多因素Logistic回归分析结果显示，T水平升高为肥胖PCOS患者转氨酶升高的独立危险因素〔OR=6.339，95%CI（1.834，21.906），P=0.004〕。

结论

肥胖PCOS患者的转氨酶升高与脂代谢紊乱、胰岛素抵抗和高雄激素血症相关，其中T水平升高是肥胖PCOS患者转氨酶升高的独立危险因素。

关键词: 多囊卵巢综合征, 肥胖, 转氨酶, 睾酮, 胰岛素抵抗, 脂代谢

CLC Number:

R711.75

王东旭,石文婧,徐樱溪等. 肥胖多囊卵巢综合征患者转氨酶升高的影响因素研究[J]. 中国全科医学, 2022, 25(03): 320-324. DOI: 10.12114/j.issn.1007-9572.2021.02.054.

Figures/Tables 4

References 23

[1]	DESWAL R, NARWAL V, DANG A，et al. The prevalence of polycystic ovary syndrome：a brief systematic review[J]. J Hum Reprod Sci，2020，13（4）：261-271. DOI：10.4103/jhrs.JHRS_95_18.
[2]	LI R, ZHANG Q F, YANG D Z，et al. Prevalence of polycystic ovary syndrome in women in China：a large community-based study[J]. Hum Reprod，2013，28（9）：2562-2569. DOI：10.1093/humrep/det262.
[3]	PASCHOU S A, POLYZOS S A, ANAGNOSTIS P，et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome[J]. Endocrine，2020，67（1）：1-8. DOI：10.1007/s12020-019-02085-7.
[4]	WU J, YAO X Y, SHI R X，et al. A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease：an update meta-analysis[J]. Reprod Health，2018，15（1）：77. DOI：10.1186/s12978-018-0519-2.
[5]	张宇恒，丁素英. 转氨酶水平与非酒精性脂肪肝的关系[J]. 郑州大学学报：医学版，2019，54（6）：916-918. DOI：10.13705/j.issn.1671-6825.2019.02.065.
[6]	LI T, ZHANG T, CUI T，et al. Involvement of endogenous testosterone in hepatic steatosis in women with polycystic ovarian syndrome[J]. J Steroid Biochem Mol Biol，2020，204：105752. DOI：10.1016/j.jsbmb.2020.105752.
[7]	Rotterdam Eshre/asrm-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome[J]. Fertil Steril，2004，81（1）：19-25. DOI：10.1016/j.fertnstert.2003.10.004.
[8]	中国肥胖问题工作组. 中国成人超重与肥胖症预防与控制指南（节录）[J]. 营养学报，2004，26（1）：1-4. DOI：10.3321/j.issn:0512-7955.2004.01.001.
[9]	SARKAR M, TERRAULT N, CHAN W，et al. Polycystic ovary syndrome （PCOS） is associated with NASH severity and advanced fibrosis[J]. Liver Int，2020，40（2）：355-359. DOI：10.1111/liv.14279.
[10]	宋华峰，胥萍. 肝脏损伤新的血清学标志物的研究进展[J]. 世界华人消化杂志，2017，25（30）：2681-2688.
[11]	LIU Q, XIE Y J, QU L H，et al. Dyslipidemia involvement in the development of polycystic ovary syndrome[J]. Taiwan J Obstet Gynecol，2019，58（4）：447-453. DOI：10.1016/j.tjog.2019.05.003.
[12]	MARí M, CABALLERO F, COLELL A，et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis[J]. Cell Metab，2006，4（3）：185-198. DOI：10.1016/j.cmet.2006.07.006.
[13]	BIEGHS V, HENDRIKX T, VAN GORP P J，et al. The cholesterol derivative 27-hydroxycholesterol reduces steatohepatitis in mice[J]. Gastroenterology，2013，144（1）：167-178.e1. DOI：10.1053/j.gastro.2012.09.062.
[14]	TOMITA K, TERATANI T, SUZUKI T，et al. Acyl-CoA：cholesterol acyltransferase 1 mediates liver fibrosis by regulating free cholesterol accumulation in hepatic stellate cells[J]. J Hepatol，2014，61（1）：98-106. DOI：10.1016/j.jhep.2014.03.018.
[15]	FINCK B N. Targeting metabolism，insulin resistance，and diabetes to treat nonalcoholic steatohepatitis[J]. Diabetes，2018，67（12）：2485-2493. DOI：10.2337/dbi18-0024.
[16]	MACUT D, TZIOMALOS K, BOZIC-ANTIC I，et al. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome[J]. Hum Reprod，2016，31（6）：1347-1353. DOI：10.1093/humrep/dew076.
[18]	SALVA-PASTOR N, CHáVEZ-TAPIA N C, URIBE M，et al. Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease[J]. J Steroid Biochem Mol Biol，2019，194：105445. DOI：10.1016/j.jsbmb.2019.105445.
	GANGALE M F, MIELE L, LANZONE A，et al. Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome[J]. Clin Endocrinol （Oxf），2011，75（4）：520-527. DOI：10.1111/j.1365-2265.2011.04093.x.
[19]	郑水，袁彦玲. PCOS发病的雄激素代谢异常机制研究进展[J]. 实用妇科内分泌电子杂志，2019，6（16）：14，18. DOI：10.16484/j.cnki.issn2095-8803.2019.16.008.
[20]	CUI P, HU W, MA T，et al. Long-term androgen excess induces insulin resistance and non-alcoholic fatty liver disease in PCOS-like rats[J]. J Steroid Biochem Mol Biol，2021，208：105829. DOI：10.1016/j.jsbmb.2021.105829.
[21]	ANZAI á, MARCONDES R R, GONÇALVES T H，et al. Impaired branched-chain amino acid metabolism may underlie the nonalcoholic fatty liver disease-like pathology of neonatal testosterone-treated female rats[J]. Sci Rep，2017，7（1）：13167. DOI：10.1038/s41598-017-13451-8.
[22]	ZHANG Y H, MENG F C, SUN X Y，et al. Hyperandrogenism and insulin resistance contribute to hepatic steatosis and inflammation in female rat liver[J]. Oncotarget，2018，9（26）：18180-18197. DOI：10.18632/oncotarget.24477.
[23]	SARKAR M A, SUZUKI A, ABDELMALEK M F，et al. Testosterone is associated with nonalcoholic steatohepatitis and fibrosis in premenopausal women with NAFLD[J]. Clin Gastroenterol Hepatol，2021，19（6）：1267-1274.e1. DOI：10.1016/j.cgh.2020.09.045.

组别	例数	年龄（岁）	BMI（kg/m²）	腰围（cm）	WHR	体脂百分比（%）	VFA（cm²）	ALT〔M（QR），U/L〕	AST〔M（QR），U/L〕	FBG（mmol/L）
单纯肥胖组	39	25.6±5.7	31.8±5.1	98.10±7.86	0.94±0.06	40.51±5.92	158.70±46.13	22.00（2.00）	18.00（9.00）	5.38±0.45
肥胖PCOS组	77	26.1±4.4	31.2±4.4	99.68±8.35	0.95±0.05	40.94±5.57	162.14±45.92	44.00（53.50）	27.00（30.50）	5.57±0.59
t（Z）值		0.346	0.694	0.978	1.559	0.309	0.307	-3.949^a	-4.038^a	1.942
P值		0.730	0.489	0.330	0.122	0.758	0.762	<0.001	<0.001	0.055

组别	例数	年龄（岁）	BMI（kg/m²）	腰围（cm）	WHR	体脂百分比（%）	VFA（cm²）	ALT〔M（QR），U/L〕	AST〔M（QR），U/L〕	FBG（mmol/L）
单纯肥胖组	39	25.6±5.7	31.8±5.1	98.10±7.86	0.94±0.06	40.51±5.92	158.70±46.13	22.00（2.00）	18.00（9.00）	5.38±0.45
肥胖PCOS组	77	26.1±4.4	31.2±4.4	99.68±8.35	0.95±0.05	40.94±5.57	162.14±45.92	44.00（53.50）	27.00（30.50）	5.57±0.59
t（Z）值		0.346	0.694	0.978	1.559	0.309	0.307	-3.949^a	-4.038^a	1.942
P值		0.730	0.489	0.330	0.122	0.758	0.762	<0.001	<0.001	0.055

项目		TG	TC	HDL	LDL	ApoB	LH	T	SHBG	FIns	HOMA-IR	FAI	LH/SH
ALT
	r_s值	0.359	0.387	-0.295	0.473	0.327	0.179	0.477	-0.157	0.369	0.357	0.464	0.152
	P值	<0.001	<0.001	0.001	<0.001	<0.001	0.054	<0.001	0.099	<0.001	<0.001	<0.001	0.103
AST
	r_s值	0.411	0.368	-0.264	0.421	0.351	0.140	0.416	-0.159	0.387	0.365	0.405	0.086
	P值	<0.001	<0.001	0.004	<0.001	<0.001	0.133	<0.001	0.094	<0.001	<0.001	<0.001	0.356

项目		TG	TC	HDL	LDL	ApoB	LH	T	SHBG	FIns	HOMA-IR	FAI	LH/SH
ALT
	r_s值	0.359	0.387	-0.295	0.473	0.327	0.179	0.477	-0.157	0.369	0.357	0.464	0.152
	P值	<0.001	<0.001	0.001	<0.001	<0.001	0.054	<0.001	0.099	<0.001	<0.001	<0.001	0.103
AST
	r_s值	0.411	0.368	-0.264	0.421	0.351	0.140	0.416	-0.159	0.387	0.365	0.405	0.086
	P值	<0.001	<0.001	0.004	<0.001	<0.001	0.133	<0.001	0.094	<0.001	<0.001	<0.001	0.356

变量	赋值
转氨酶	ALT>40 U/L和/或AST>35 U/L=1，ALT≤40 U/L且AST≤35 U/L=0
TG	≥1.40 mmol/L=1，<1.40 mmol/L=0
TC	≥4.79 mmol/L=1，<4.79 mmol/L=0
HDL	≥1.23 mmol/L=1，<1.23 mmol/L=0
LDL	≥2.91 mmol/L=1，<2.91 mmol/L=0
ApoB	≥0.94 g/L=1，<0.94 g/L=0
T	≥2.18 nmol/L=1，T<2.18 nmol/L=0
FIns	≥19.70 mU/L=1，<19.70 mU/L=0
HOMA-IR	≥4.70=1，<4.70=0
FAI	≥11.78%=1，<11.78%=0

肥胖多囊卵巢综合征患者转氨酶升高的影响因素研究

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 23

Related Articles 15

Recommended Articles

Metrics

Comments

变量	β值	标准误	Waldχ²值	P值	OR值	95%CI
TG	0.830	0.561	2.403	0.121	2.388	（0.794，7.176）
TC	0.225	0.782	0.083	0.773	1.253	（0.270，5.801）
HDL	-0.167	0.556	0.090	0.764	0.846	（0.285，2.516）
LDL	0.665	0.825	0.649	0.420	1.944	（0.386，9.787）
ApoB	-0.515	0.751	0.471	0.597	0.597	（0.137，2.603）
T	1.847	0.633	8.518	0.004	6.339	（1.834，21.906）
FIns	1.014	0.830	1.490	0.222	2.755	（0.541，14.726）
HOMA-IR	0.415	0.827	0.251	0.616	1.514	（0.299，7.663）
FAI	0.003	0.636	<0.001	0.996	1.003	（0.228，3.491）

[1]	HAN Congcong, QIU Xinyu, SHAN Chunfang, SONG Ning, CHEN Qingjie, MULADILI· Abudureheman, LI Xiaomei, YANG Yining, ZHAO Qian. Impact of Metabolic Obesity Phenotype on Long-term Prognosis after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome [J]. Chinese General Practice, 2026, 29(21): 2950-2958.
[2]	ZHANG Ke, ZENG Xianchang, ZOLZAYA Enkhzaya, ZHU Yelin, HUANG Yiwen, LIU Zhenxiu, TAO Feng. Effect of Xiere Xingpi Yin on Eating Behaviors and Weight-related Outcomes in Patients with Obesity: a Randomized Controlled Trial [J]. Chinese General Practice, 2026, 29(20): 2759-2765.
[3]	REYILAI· Maimaiti, ZHOU Yiran, WU Yun, LIU Zhencheng, LU Yaoqin, WU Haiyan. Association between Novel Obesity Indicators and Cardiovascular Disease Risk in Hypertensive Patients [J]. Chinese General Practice, 2026, 29(20): 2836-2845.
[4]	WU Zhen, XI Yaqi, HU Linlin. Characteristics of Policy Instrument Selection and Combination for Weight Management in China: a Content Analysis of National Policy Documents (2016-2025) [J]. Chinese General Practice, 2026, 29(20): 2766-2774.
[5]	CHEN Xiangyang, HUANG Hongmei, LI Sheyu. Prevention and Management of Adult Obesity: Progress and Trends from Six Keywords in 2025 [J]. Chinese General Practice, 2026, 29(20): 2753-2758.
[6]	TANG Lijuan, QI Qi, ZHANG Fan, GAO Yifu, CAO Yajing, YUE Fujuan, GAO Jinchai, LIU Xiaoli. Characterisation of the Prevalence of Overweight/Obesity among Residents Aged 18-44 Years in Hebei Province in 2013 and 2020 [J]. Chinese General Practice, 2026, 29(19): 2695-2704.
[7]	LI Yachan, YANG Yang, XU Qianting, KE Tingyu. Association between the Chinese Visceral Adiposity Index and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(18): 2482-2488.
[8]	LI Simin, ZHANG Tingting, WANG Kunbo, YANG Jianzhou, PING Weiwei. Effects of Exercise Dosage on Elderly Patients with Sarcopenia: a Meta-analysis [J]. Chinese General Practice, 2026, 29(17): 2400-2409.
[9]	Chinese Nutrition Society Obesity Prevention and Control Branch. Chinese Guidelines for Behavioral and Lifestyle Interventions for Obesity [J]. Chinese General Practice, 2026, 29(16): 2113-2139.
[10]	LI Jiali, LIU Fan, KE Lixin, LI Huijuan, WANG Haibo, ZHAO Xiaoxiao, ZHAO Xinke, LU Cuncun. Disease Burden of Obesity among Individuals Aged 60 and above Globally and in China from 1990 to 2021: Trend Analysis and Model-based Projection [J]. Chinese General Practice, 2026, 29(15): 2067-2076.
[11]	CHEN Xiaolong, JIN Jing, HUA Jialu, LI Yuyu, PAN Youjia, PAN Qi, TU Chunjing, WANG Ping. Study on the Optimal Time-use Composition of 24-hour Movement Behaviors for Obesity Prevention in College Students [J]. Chinese General Practice, 2026, 29(12): 1525-1532.
[12]	YANG Lei, GUAN Hua. Application Progress of Generative Artificial Intelligence in Weight Management [J]. Chinese General Practice, 2026, 29(12): 1533-1540.
[13]	YAN Manli, ZHANG Baoqing, HUANG Lei, LI Xiang. A New Chapter in Obesity Treatment: Mechanisms and Clinical Research Progress of Multi-target Peptide Agonists [J]. Chinese General Practice, 2026, 29(12): 1511-1519.
[14]	HE Zhiguang, QIU Shanjiao, CHEN Zhang, LI Anchun, HUANG Wenjing. Interpretation and Discussion of the RACGP Guidelines for Preventive Activities in General Practice: Screening for Weight Issues and Preventive Strategies [J]. Chinese General Practice, 2026, 29(12): 1505-1510.
[15]	CHEN Yiming, HUANG Yiling, JI Fei, LYU Ling, HUANG Yu, WU Zeyu, HANG Qiqi, PING Fan, YANG Meng. Hepatic-glycemic Interdependence: the Bidirectional Relationship between Type 2 Diabetes and MASLD and Emerging Therapeutic Strategies [J]. Chinese General Practice, 2026, 29(12): 1497-1504.